Document is current

Article History

Received: 14 November 2018

Accepted: 13 January 2019

First Online: 1 February 2019

Ethics approval and consent to participate

: Existing de-identified specimens and associated clinical data was submitted to OmniSeq from Roswell Park Comprehensive Cancer Center (Buffalo, NY), Fox Chase Cancer Center (Philadelphia, PA), Dartmouth-Hitchcock Medical Center (Lebanon, NH), Northwest Oncology (Munster, IN), Hospital Universitario Virgen Macarena (Sevilla, Spain), Duke Cancer Institute (Durham, North Carolina), Mission Health (Ashville, North Carolina), Meharry Medical College (Nashville, Tennessee), and Medical College of Wisconsin (Milwaukee, WI) upon IRB approval from each individual institution. OmniSeq studies based on de-identified data were considered non-human subjects research under IRB-approved protocol (BDR #080316) at Roswell Park Comprehensive Cancer Center (Buffalo, NY).

: Not applicable.

: MZ, PG, KD, KS, KGM, LJT, NS, DK, IAF, DM, JZ, ML, ACMK, JT, RS, LD, AS, SM, RJ, OB, and MS have no competing interests to disclose. SP, JMC, MKN, STG, APS, BB. JH, VG, JA, FLL, YW, MG, and CM are employees of OmniSeq, Inc. (Buffalo, NY) and hold restricted stock in OmniSeq, Inc. GD, EY, AE, HC, WB, CM, STG, MSE, KO, and JC are employees of Roswell Park Comprehensive Cancer Center (Buffalo, NY), which is the majority shareholder of OmniSeq, Inc.. LG provides remunerated consulting to OmniSeq, Inc., and is supported by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine (New York, US) and by donations from Sotio a.s. (Prague, Czech Republic), Phosplatin (New York, NY, US), and the Luke Heller TECPR2 Foundation (Boston, MA, US). JC is supported by grants from Bristol-Myeres Squibb and Medpacto, is a site PI for Bristol-Myers Squibb, Genentech, Spectrum, Adaptimmune, Medpacto, Bayer, AbbVie, and Moderna, and has spoken on behalf of Merck and Guardant. TZ has received consulting fees from Genentech Roche, Sanofi-Aventis, Astra Zeneca, Bayer, Janssen, Pfizer, Foundation Medicine, Pharmacyclics, Bristol Myers Squibb, and MAA Laboratories, promotional service fees from Genentech Roche and Exelixis, contracted research with Janssen, Pfizer, OmniSeq, PGDx, Novartis, Merrimack, Abbvie/StemCentrx, Acerta, Merck, and Regeneron, and ownership interest in Capio Biosciences. RK has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health,Grifols, and Konica Minolta, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Roche and NeoMed, and receives speaker fees from Roche, and has equity in IDbyDNA, and CureMatch, Inc.. BG is a consultant for Celgene, Cook Medical, Merrimack, Foundation Medicine, Ipsen, Bristol Myers Squibb, Exelixis, Terumo Interventional Systems, and Taiho Oncology.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.